Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Paras Defence IPO Date, Review, Price, Form & Market Lot Details

By Jagat Joshi
September 20, 2021

Paras Defence and Space Technologies Limited IPO to hit the market on 21 September as per the RHP documents filed with SEBI. The Paras Defence IPO comprises ₹140.6 crore of fresh issue and the offer for sale up to 1,724,490 equity shares of ₹10. The IPO to close on 23 September. The company might list on the indices on 1 October.

Paras Defence and Space Technologies is India’s most progressive Tier 2 defence engineering company. The offer wide range of defence products and solutions. They are the only manufacturer of Infrared Optics in large quantities in India. They are contributing prestigious Defence & Space Programs of our country. They are involved in five verticals namely Defence & Space Optics, Defence Electronics, Heavy Engineering, Electromagnetic Pulse Protection Solutions and Niche Technologies. Check out Paras Defence IPO details.

The Expected Subscription for the Paras Defence IPO might be 150x in Retail and 500x in NII.

Important Details:

40+ Years of sustained business growth in Defence & Space Engineering area
Only manufacturer of Infrared Optics in large quantities in India
Manufacturing setup with 400+ workforce
IPO funds will be utilized to buy machinery and equipment, working capitals, reply of borrowings and general corporate purposes

Customer List has big names: Isro, Defence R&D Organization, Bharat Electronics, Cochin Shipyard, Hindustan Aeronautics Limited, Garden Reach Shipbuilders & Engineers, Bharat Dynamics Ltd, BrahMos, CSIR NAL, Electronics Corporation of India Limited, Goshi, Goa Shipyard, Hindustan Shipyard Limited, iia, Indian Institute of Astrophysics, Mado, Mazagon Dock Shipbuilders Ltd, National Physical Laboratory, Ordnance Factory Board, Sameer, Israel Aerospace Industries, Elbit Systems, Rafael Advanced Defense Systems, STELOP, L3 MAPPS, Safran, Chaban Group, Advanced Mechanical and Optical Systems, TAE YOUNG OPTICS, Alpha Design Technologies, Godrej & Boyce, Kirloskar Group, L & T, MKU, Premier Explosives Limited, Solar, Solar Industries, Tata Consultancy Services, TATA Power, ASTRA RAFAEL COMSYS PVT LTD.

Paras Defence IPO Review

Apply with Short Term & Long Term View

Brokerage Firm IPO Reviews

Axis Bank: Neutral
Capital Market: May Apply
Choice Broking: Apply
Hem Securities: Apply
JM Financial: Neutral
Reliance Securities: Neutral
Religare Broking: Neutral

Paras Defence IPO Date & Price Band

IPO Open:	21 September 2021
IPO Close:	23 September 2021
IPO Size:	Approx ₹170.78 Crores
Fresh Issue:	Approx ₹140.60 Crores
Offer for Sale:	Approx ₹30.18 Crores (1,724,490 Eq. Shares)
Face Value:	₹10 Per Equity Share
Price Band:	₹165 to ₹175 Per Share
Listing on:	BSE & NSE
Retail Portion:	35%
QIB Portion:	50%
NII Portion:	15%
Discount:	₹- per equity share for Employees
DRHP Draft Prospectus:	Click Here
DRHP Draft Prospectus:	Click Here

Paras Defence IPO Market Lot

The Paras Defence IPO minimum market lot is 85 shares with ₹14,875 application amount. The retail investors can apply up-to 13 lots, 1105 shares with ₹1,93,375 application amount.

Minimum Lot Size:	Minimum 85 Shares for 1 lot
Minimum Amount:	₹14,875 for 1 lot
Maximum Lot Size:	Maximum 1105 Shares for 13 lot
Maximum Amount:	₹1,93,375 for 13 lot

Paras Defence IPO Date, Time Table, Allotment & Listing

The Paras Defence IPO date is 21 September 2021 and the IPO close date is 23 September 2021. The allotment date is 28 September 2021 and the IPO may list on 01 October 2021.

Price Band Announcement:	15 September 2021
Anchor Investors Allotment:	20 September 2021
IPO Open Date:	21 September 2021
IPO Close Date:	23 September 2021
Basis of Allotment:	28 September 2021
Refunds:	29 September 2021
Credit to Demat Account:	30 September 2021
IPO Listing Date:	1 October 2021

Paras Defence IPO Form

How to apply the Paras Defence IPO? You can apply Paras Defence IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the Paras Defence IPO in the Invest section. The other option you can apply Paras Defence IPO via IPO forms download via NSE and BSE. Check out the Paras Defence forms – click NSE Forms & BSE Forms blank IPO forms download, fill and submit in your bank or with your broker.

Paras Defence Company Financial Report

₹ in Crores
	Assets	Revenue	Expense	PAT
2019	₹330	₹157	₹130	₹18.97
2020	₹342	₹148	₹127	₹19.66
2021	₹363	₹145	₹122	₹15.79

Company Promoters

Sharad Virji Shah
Munjal Sharad Shah

Paras Defence IPO Registrar

Link Intime India Private Limited
C-101, 1 st Floor
247 Park, L.B.S Marg, Vikhroli (West)
Mumbai 400 083
Maharashtra, India
Tel: +91 22 4918 6200
E-mail: parasdefence.ipo @linkintime.co.in
Investor grievance E-mail: parasdefence.ipo@linkintime.co.in
Contact Person: Shanti Gopalkrishnan
Website: www.linkintime.co.in
SEBI Registration No.: INR000004058

Note: Check Paras Defence IPO allotment status on Linkintime website allotment URL. Click Here

Paras Defence IPO Lead Managers

Anand Rathi Advisors Limited

Company Address

Paras Defence & Space Technologies Ltd
D-112, TTC Industrial Area,
MIDC, Nerul, Navi Mumbai – 400 706
Maharashtra, India
Tel: +91 22 6919 9999
Contact Person: Ajit Sharma
Company Secretary and Compliance Officer
Tel: +91 22 6919 9999
E-mail: ir@parasdefence.com
Website: www.parasdefence.com
Corporate Identity Number: U29253MH2009PLC193352

Paras Defence IPO FAQs

What is Paras Defence IPO?

Paras Defence IPO is a main-board IPO. They are going to raise ₹170.78 Crores via IPO. The issue is priced at ₹165 to ₹175 per equity share. The IPO to be listed on BSE & NSE.

When Paras Defence IPO will open?

The IPO is to open on 21 September 2021 for QIB, NII, and Retail Investors.

What is Paras Defence IPO Investors Portion?

The investors’ portion for QIB 50%, NII 15%, and Retail 35%.

How to Apply the Paras Defence IPO?

You can apply Paras Defence IPO via ASBA online via your bank account. You can also apply ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the Paras Defence IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “Paras Defence Finance”. Click on Bid Button. Enter your UPI ID, Quantity and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the Paras Defence IPO through Upstox?

Log in to Upstox Application with your credentials. Select the IPO. You will see the IPO Name “Paras Defence Finance”. Click on Bid Button. Confirm your application. Now go to your UPI App on Net Banking or BHIM App to Approve – mandate. Open Demat Account with Upstox.

What is Paras Defence IPO Size?

Paras Defence IPO size is ₹170.78 crores. The IPO comprises ₹140.60 crores of fresh issue and offer for sale of 1,724,490 equity shares.

What is Paras Defence IPO Price Band?

Paras Defence IPO Price Band is ₹165 to ₹175 per equity share.

What is Paras Defence IPO Minimum and Maximum Lot Size?

The minimum bid is 85 shares with ₹14,875 amount while maximum bid is 1105 shares with ₹1,93,375.

What is Paras Defence IPO Allotment Date?

Paras Defence IPO allotment date is 28 September 2021.

What is Paras Defence IPO Listing Date?

Paras Defence IPO listing date is 01 October 2021. The IPO to list on BSE and NSE.

Note: The Paras Defence IPO details is announced officially. The IPO grey market premium (Paras Defence IPO Premium) is updated on their particular page. You can check our IPO grey market page for daily updates.)

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.